| Development of a pharmacist-managed lipid clinic. | |
| | |
MedLine Citation:
|
PMID: 11978169 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
OBJECTIVE: To describe the development of a pharmacist-managed lipid clinic within a primary care medical clinic and review its results after approximately 12 months of operation. METHODS: A pharmacist-managed lipid clinic was developed at Naval Medical Center San Diego. Administrative background, treatment algorithm development, operational issues, clinical activities, and barriers to the clinic are discussed. For intermediate outcomes, data from patients who had at least 1 intervention by the pharmacist and 1 follow-up lipid panel were analyzed for medication use, changes in lipid parameters, and percent reaching the low-density-lipoprotein (LDL) target goal. Modified National Cholesterol Education Program-Adult Treatment Panel II guidelines were used to determine the LDL goal. RESULTS: Following approximately 12 months of operation, the clinic received 204 referrals and consisted of 146 active patients. A brief study was conducted to assess clinical outcomes. Of 115 patients who were seen in the clinic and met inclusion criteria, 57% were receiving treatment with a hydroxymethylglutaryl coenzyme A reductase inhibitor (statin) and 17% were receiving fibrates; 17% of the patients were not receiving lipid-lowering medications. Relative to baseline, LDL cholesterol concentrations decreased 20%, high-density-lipoprotein cholesterol increased 11%, and triglycerides decreased 19%. Overall, LDL goals were reached in 77% of the patients. LDL goals were attained by 63%, 79%, and 93% of patients with targets of <100, <130, and <160 mg/dL, respectively. Results are compared with other studies regarding lipid goal attainment. CONCLUSIONS: A pharmacist-managed lipid clinic can be developed and integrated into a primary care medical clinic. Pharmacists can effectively manage lipid-lowering therapy, helping to achieve LDL goals. |
| | |
Authors:
|
Margaret A Cording; Emily B Engelbrecht-Zadvorny; B Jill Pettit; John H Eastham; Rheta Sandoval |
Related Documents
:
|
16274999 - Effects of atorvastatin on arterial endothelial function in coronary bypass surgery. 21272339 - Reduction of exacerbations by the pde4 inhibitor roflumilast--the importance of definin... 10555389 - Prevention of cardiovascular events by hypolipidemic therapy evidence-based medicine cr... 12718459 - Gender differences in secondary prevention of coronary heart disease: reasons to worry ... 17434849 - Pravastatin in hiv-infected patients treated with protease inhibitors: a placebo-contro... 16464519 - Short-term atorvastatin treatment enhances specific antibody production following tetan... 17822339 - Venlafaxine in the treatment of children and adolescents with attention-deficit/hyperac... 12946289 - Epidemiology of fibromyalgia. 21145719 - Clinical predictors of frequent exacerbations in subjects with severe chronic obstructi... |
Publication Detail:
|
Type: Journal Article |
Journal Detail:
|
Title: The Annals of pharmacotherapy Volume: 36 ISSN: 1060-0280 ISO Abbreviation: Ann Pharmacother Publication Date: 2002 May |
Date Detail:
|
Created Date: 2002-04-29 Completed Date: 2002-10-18 Revised Date: 2006-11-15 |
Medline Journal Info:
|
Nlm Unique ID: 9203131 Medline TA: Ann Pharmacother Country: United States |
Other Details:
|
Languages: eng Pagination: 892-904 Citation Subset: IM |
Affiliation:
|
Department of Pharmacy, Naval Medical Center San Diego, 34800 Bob Wilson Drive, San Diego, CA 92134-1113, USA. macording@nmcsd.med.navy.mil |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Algorithms Ambulatory Care Facilities / organization & administration* Antilipemic Agents / therapeutic use Cholesterol, LDL / blood* Drug Monitoring / methods Forms and Records Control / organization & administration Humans Hydroxymethylglutaryl-CoA Reductase Inhibitors / therapeutic use Patient Acceptance of Health Care Pharmacists / organization & administration* Pharmacy Administration / methods* Referral and Consultation Treatment Outcome Workload |
| Chemical | |
Reg. No./Substance:
|
0/Antilipemic Agents; 0/Cholesterol, LDL; 0/Hydroxymethylglutaryl-CoA Reductase Inhibitors |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Continuous infusion of coagulation factor products.
Next Document: Flavopiridol, a novel cyclin-dependent kinase inhibitor, in clinical development.